xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

556

International consensus statement on rhinosinusitis

Pregabalin is more effective and with lower adverse events compared to acetaminophen for patients undergoing ESS.

Monitored anesthesia care combined with preoperative analgesia with a low dose of (600 mg) oral gabapentin is an efficient option with tolerable side effects.

Gabapentin decreased dose requirements of intraoperative hypotensive agent and postoperative morphine, without signifcant side effects.

Gabapentin provides a significant analgesic benefit for intraoperative and postoperative pain relief in patients undergoing nasal surgery, but is

associated with increased risk of dizziness.

Study Year LOE Design Study Groups Clinical Endpoint Conclusions Gabapentinoids

VAS at immediately post-op, 12, 24, 48, and 72 hours Adverse events Hemodynamics

Intraoperative VAS at 5, 15, 30, 45, and 60 minutes Postoperative VAS at 30

minutes and 2, 4, 6, 12, and 24hours Total consumption of

remifentanil and propofol

Intraoperative VRS at 5, 15, 30, 45, and 60 minutes Postoperative VAS at 30

minutes and 2, 4, 6, 12, and 24hours

Time to first analgesic need

Postoperative VAS at 1 hour Opioid usage Adverse events

Total fentanyl consumption

Time to first analgesic need

Scheduled Pregabalin 50 mg 3 times daily PO (35)

Scheduled Acetaminophen 500 mg, 4 times daily PO

Gabapentin 600 mg PO (30) Placebo PO (30)

given 1 hour prior to surgery

Mohammed 1902 2012 2 RCT Gabapentin 1.2 gm PO (40) Placebo PO (40) Kazak 1879 2010 2 Prospective, DB RCT

Gabapentin 1200 mg PO (25) Placebo PO (25)

given 1 hour prior to surgery

Rezaeian 1901 2017 2 Prospective, DB RCT

Turan 1880 2004 2 Prospective, DB RCT

TABLE XII-4 (Continued)

d Downgraded due to randomization not described e Downgraded due to VAS only assessed at 1 time point

a Downgraded due to outcome measures used. b Downgraded due to no randomization c Downgraded due to no blinding